Li Xiang, Anderson Marie, Collin Delphine, Muegge Ingo, Wan John, Brennan Debra, Kugler Stanley, Terenzio Donna, Kennedy Charles, Lin Siqi, Labadia Mark E, Cook Brian, Hughes Robert, Farrow Neil A
Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368.
Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368.
J Biol Chem. 2017 Jul 14;292(28):11618-11630. doi: 10.1074/jbc.M117.789024. Epub 2017 May 25.
The nuclear receptor retinoid acid receptor-related orphan receptor γt (RORγt) is a master regulator of the Th17/IL-17 pathway that plays crucial roles in the pathogenesis of autoimmunity. RORγt has recently emerged as a highly promising target for treatment of a number of autoimmune diseases. Through high-throughput screening, we previously identified several classes of inverse agonists for RORγt. Here, we report the crystal structures for the ligand-binding domain of RORγt in both apo and ligand-bound states. We show that apo RORγt adopts an active conformation capable of recruiting coactivator peptides and present a detailed analysis of the structural determinants that stabilize helix 12 (H12) of RORγt in the active state in the absence of a ligand. The structures of ligand-bound RORγt reveal that binding of the inverse agonists disrupts critical interactions that stabilize H12. This destabilizing effect is supported by calculations and experimentally by a normalized crystallographic B-factor analysis. Of note, the H12 destabilization in the active state shifts the conformational equilibrium of RORγt toward an inactive state, which underlies the molecular mechanism of action for the inverse agonists reported here. Our findings highlight that nuclear receptor structure and function are dictated by a dynamic conformational equilibrium and that subtle changes in ligand structures can shift this equilibrium in opposite directions, leading to a functional switch from agonists to inverse agonists.
核受体视黄酸受体相关孤儿受体γt(RORγt)是Th17/白细胞介素-17途径的主要调节因子,在自身免疫发病机制中起关键作用。RORγt最近已成为治疗多种自身免疫性疾病的极有前景的靶点。通过高通量筛选,我们之前鉴定出了几类RORγt的反向激动剂。在此,我们报道了RORγt配体结合结构域在无配体和有配体结合状态下的晶体结构。我们表明,无配体的RORγt采用能够招募共激活肽的活性构象,并对在无配体情况下稳定RORγt活性状态下螺旋12(H12)的结构决定因素进行了详细分析。有配体结合的RORγt结构表明,反向激动剂的结合破坏了稳定H12的关键相互作用。这种去稳定作用通过计算得到支持,并通过归一化晶体学B因子分析在实验上得到证实。值得注意的是,活性状态下的H12去稳定化使RORγt的构象平衡向非活性状态移动,这是本文报道的反向激动剂作用分子机制的基础。我们的研究结果突出表明,核受体的结构和功能由动态构象平衡决定,配体结构的细微变化可使这种平衡向相反方向移动,导致从激动剂到反向激动剂的功能转换。